Nilo Saúde

About Nilo Saúde

Nilo Saúde is a Brazilian health-tech company founded in 2020 by Isadora Kimura, Victor Marcondes, and Rodrigo Grossi. The company provides a B2B software-as-a-service (SaaS) platform designed to improve the relationship and care management between healthcare providers and their patients. Initially conceived as a digital multidisciplinary clinic for the 50+ demographic, the founders identified a larger market need for digital tools among traditional healthcare players, especially as the COVID-19 pandemic accelerated the adoption of telemedicine. This led to a pivot to a B2B model, offering a white-label platform for health insurers, hospitals, clinics, and other healthcare organizations to create and manage digital health services.

The founders' backgrounds are rooted in technology and healthcare. Isadora Kimura has an MBA from Stanford and experience at a mental health startup in Silicon Valley. Victor Marcondes, though an engineer, comes from a family of doctors and holds an MBA from Harvard. Rodrigo Grossi has a master's and doctorate from ITA and has a history of applying technology to the health sector, including a role as a former technology director at Bionexo. Their collective personal experiences with family health challenges highlighted the difficulties in navigating patient care, inspiring the creation of Nilo.

Nilo's platform serves as an intelligent and automated system that centralizes patient information and communications. It enables healthcare providers to manage patient journeys, from initial contact and scheduling to ongoing care and follow-ups, through a unified command center. A key feature is its integration with WhatsApp, which allows healthcare teams to interact with patients for appointment reminders, exam results, and telehealth consultations without the professionals needing to use WhatsApp Business directly. In 2024, the company integrated generative AI into its platform, introducing a virtual agent named Clara to automate repetitive tasks like scheduling and triage, and to structure unstructured data from sources like audio messages and exam images into actionable insights for care teams. This AI capability aims to increase operational efficiency, reduce costs, and allow healthcare professionals to focus more on patient care.

The company's business model is B2B, targeting clients such as health insurers, hospitals, and clinics with its SaaS platform. Its client roster includes major players like Grupo NotreDame Intermédica, Porto Seguro, and Leve Saúde. Nilo Saúde has secured significant funding to fuel its growth, including a Series A round of BRL 55 million (approximately USD 10 million) in January 2022, co-led by SoftBank Latin America Fund and Global Founders Capital (GFC), with participation from existing investors Canary and MAYA Capital. The company aims to expand its team and technology, with a goal of reaching 10 million patients on its platform.